We are pleased to announce that Cellis has been featured in the recently published review, “Smart Cell Therapy: An Industry Perspective on Macrophages as Living Drugs” (Cytotherapy, December 2024). This review examines the growing potential of macrophage-based cell therapies, which offer unique advantages over traditional methods. Macrophages are capable of targeting diseases both systemically and locally by orchestrating innate and adaptive immune responses. Their ability to perform complex effector functions and utilize multiple components of the immune system positions them as a promising tool in the fight against cancer and other diseases.
Cellis’ innovative Macrophage Drug Conjugate (MDC) technology is highlighted as a key example of this potential. MDCs enable the targeted delivery of therapeutic agents directly to cancer cells, offering a novel approach to tumor treatment and advancing the field of precision oncology.
As we prepare for clinical trials of MDC-735 for glioblastoma, our commitment remains strong in overcoming the critical challenges in the development of macrophage-based therapies and driving meaningful progress in oncology care.
Read the full article here: https://www.sciencedirect.com/science/article/pii/S1465324924009484
